Ansprechen auf eine docetaxel-therapie im LNCaP-Prostatakarzinom-Xenograft-Mausmodell: Untersuchung mit der [11C]Cholin-Kleintier-PET/CT;[11C]choline as a pharmacodynamic marker for docetaxel therapy response assessment in a LNCaP prostate cancer xenograft mouse model

NuklearMedizin

Volumn 52, Issue 4, 2013, Pages 141-147

  Schwarzenbock S ^a,d   Sachs, D ^a   Souvatzoglou, M ^a   Schuster, T ^b   Nawroth, R ^a   Weirich, G ^a   Treiber, U ^a   Wester, H J ^c   Ziegler, S ^a   Schwaiger, M ^a   Senekowitsch Schmidtke, R ^a   Krause, B J ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Choline; Docetaxel; LNCaP; Prostate cancer; Small animal PET CT; Therapy response; Xenograft model

Indexed keywords

CHOLINE C 11; DOCETAXEL; ANTINEOPLASTIC AGENT; CARBON; CHOLINE; RADIOPHARMACEUTICAL AGENT; TAXOID; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; DIAGNOSTIC USE; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; REPRODUCIBILITY; SCID MOUSE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL LINE; METHODOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHOLINE; MALE; MICE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TREATMENT OUTCOME;

EID: 84881482552     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0521-12-07     Document Type: Article

References (19)

1. Anderson J, Abrahamsson PA, Crawford D et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 2008; 101: 1497-1501.
2. Belloli S, Jachetti E, Moresco RM et al. Characterization of preclinical models of prostate cancer using PET-based molecular imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1245-1255.
3. Damber JE, Aus G. Prostate cancer. Lancet 2008; 371: 1710-1721.
4. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996; 51: 1075-1092.
5. Kolfschoten GM, Hulscher TM, Duyndam MC et al. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 2002; 63: 733-743.
6. 11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur J Nucl Med Mol Imaging 2010; 37: 1861-1868.
7. Li Y, Li X, Hussain M et al. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004; 6: 158-167.
8. Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec 2001; 1: 195-211.
9. Muller SA, Holzapfel K, Seidl C et al. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging 2009; 36: 1434-1442.
10. Oudard S, Legrier ME, Boye K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-1734.
11. Oyama N, Akino H, Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001; 22: 963-969.
12. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4: 99-104.
13. Oyama N, Akino H, Suzuki Y et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-629.
14. 11C-choline. J Labelled Cpd Radiopharm 2000; 43: 195-203.
15. Price DT, Coleman RE, Liao RP et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168: 273-280.
16. Sonpavde G, Sternberg CN. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. Int J Urol 2010; 17: 228-240.
17. Tang Y, Khan MA, Goloubeva O et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 169-174.
18. Wang Y, Revelo MP, Sudilovsky D et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005; 64: 149-159.
19. 11C] Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 2004; 12: 2887-2893.